Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis

Journal of Immunology

Volumn 184, Issue 7, 2010, Pages 3907-3916

  Ciorba, Matthew A ^a   Bettonville, Ellen E ^a   McDonald, Keely G ^a   Metz, Richard ^b   Prendergast, George C ^c,d   Newberry, Rodney D ^a   Stenson, William F ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b NEWLINK GENETICS   (United States)

^c LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD11B ANTIGEN; DNA; GLYCOPROTEIN P 15095; INDOLEAMINE 2,3 DIOXYGENASE; INTERFERON; OLIGODEOXYNUCLEOTIDE; STAT1 PROTEIN; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TRINITROBENZENESULFONIC ACID; DEXTRAN SULFATE; IMMUNOLOGICAL ADJUVANT; ISOENZYME; OLIGODEOXYRIBONUCLEOTIDE;

ADAPTIVE IMMUNITY; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; ARTICLE; COLITIS; COMMENSAL; CONTROLLED STUDY; DISEASE SEVERITY; ENTERITIS; ENZYME INDUCTION; ENZYME INHIBITION; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LAMINA PROPRIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG POTENTIATION; ENZYMOLOGY; FLUORESCENT ANTIBODY TECHNIQUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; MOUSE MUTANT; MUCOSA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLITIS; DEXTRAN SULFATE; DNA; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; INTESTINAL MUCOSA; ISOENZYMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MUCOUS MEMBRANE; OLIGODEOXYRIBONUCLEOTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 9; TRINITROBENZENESULFONIC ACID;

EID: 77951635953     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0900291     Document Type: Article

References (52)

1. MacKenzie, C. R., K. Heseler, A. Müller, and W. Däubener. 2007. Role of indoleamine 2,3-dioxygenase in antimicrobial defence and immuno-regulation: tryptophan depletion versus production of toxic kynurenines. Curr. Drug Metab. 8: 237-244.
2. Mellor, A. L., and D. H. Munn. 2004. IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat. Rev. Immunol. 4: 762-774.
3. + dendritic cells to acquire potent indoleamine 2,3-dioxygenase- dependent T cell regulatory functions via IFN type 1 signaling. J. Immunol. 175: 5601-5605.
4. Metz, R., J. B. Duhadaway, U. Kamasani, L. Laury-Kleintop, A. J. Muller, and G. C. Prendergast. 2007. Novel tryptophan catabolic enzyme IDO2 is the preferred biochemical target of the antitumor indoleamine 2,3-dioxygenase inhibitory compound D-1-methyl-tryptophan. Cancer Res. 67: 7082-7087. (Pubitemid 47206533)
5. Ball, H. J., A. Sanchez-Perez, S. Weiser, C. J. Austin, F. Astelbauer, J. Miu, J. A. McQuillan, R. Stocker, L. S. Jermiin, and N. H. Hunt. 2007. Characterization of an indoleamine 2,3-dioxygenase-like protein found in humans and mice. Gene 396: 203-213.
6. Ball, H. J., H. J. Yuasa, C. J. Austin, S. Weiser, and N. H. Hunt. 2009. Indoleamine 2,3-dioxygenase-2; a new enzyme in the kynurenine pathway. Int. J. Biochem. Cell Biol. 41: 467-471.
7. Munn, D. H., M. D. Sharma, B. Baban, H. P. Harding, Y. Zhang, D. Ron, and A. L. Mellor. 2005. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22: 633-642.
8. Mellor, A. L., and D. H. Munn. 2008. Creating immune privilege: active local suppression that benefits friends, but protects foes. Nat. Rev. Immunol. 8: 74-80.
9. Penberthy, W. T. 2007. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr. Drug Metab. 8: 245-266.
10. Hayashi, T., L. Beck, C. Rossetto, X. Gong, O. Takikawa, K. Takabayashi, D. H. Broide, D. A. Carson, and E. Raz. 2004. Inhibition of experimental asthma by indoleamine 2,3-dioxygenase. J. Clin. Invest. 114: 270-279.
11. Hayashi, T., S. P. Rao, K. Takabayashi, J. H. Van Uden, R. S. Kornbluth, S. M. Baird, M. W. Taylor, D. A. Carson, A. Catanzaro, and E. Raz. 2001. Enhancement of innate immunity against Mycobacterium avium infection by immunostimulatory DNA is mediated by indoleamine 2,3-dioxygenase. Infect. Immun. 69: 6156-6164.
12. Hayaishi, O. 1976. Properties and function of indoleamine 2,3-dioxygenase. J. Biochem. 79: 13P-21P.
13. Ferdinande, L., P. Demetter, C. Perez-Novo, A. Waeytens, J. Taildeman, I. Rottiers, P. Rottiers, M. De Vos, and C. A. Cuvelier. 2008. Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int. J. Immunopathol. Pharmacol. 21: 289-295.
14. Barceló-Batllori, S., M. André, C. Servis, N. Lévy, O. Takikawa, P. Michetti, M. Reymond, and E. Felley-Bosco. 2002. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2: 551-560. (Pubitemid 34507345)
15. Dieckgraefe, B. K., W. F. Stenson, J. R. Korzenik, P. E. Swanson, and C. A. Harrington. 2000. Analysis of mucosal gene expression in inflammatory bowel disease by parallel oligonucleotide arrays. Physiol. Genomics 4: 1-11.
16. Wolf, A. M., D. Wolf, H. Rumpold, A. R. Moschen, A. Kaser, P. Obrist, D. Fuchs, G. Brandacher, C. Winkler, K. Geboes, et al. 2004. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin. Immunol. 113: 47-55.
17. Gurtner, G. J., R. D. Newberry, S. R. Schloemann, K. G. McDonald, and W. F. Stenson. 2003. Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology 125: 1762-1773.
18. Rachmilewitz, D., F. Karmeli, K. Takabayashi, T. Hayashi, L. Leider-Trejo, J. Lee, L. M. Leoni, and E. Raz. 2002. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology 122: 1428-1441. (Pubitemid 34465184)
19. Fichtner-Feigl, S., I. J. Fuss, C. A. Young, T. Watanabe, E. K. Geissler, H. J. Schlitt, A. Kitani, and W. Strober. 2007. Induction of IL-13 triggers TGFβ1-dependent tissue fibrosis in chronic 2,4,6-trinitrobenzene sulfonic acid colitis. J. Immunol. 178: 5859-5870.
20. Lawrance, I. C., F. Wu, A. Z. Leite, J. Willis, G. A. West, C. Fiocchi, and S. Chakravarti. 2003. A murine model of chronic inflammation-induced intestinal fibrosis down-regulated by antisense NF-κB. Gastroenterology 125: 1750-1761.
21. Colón, A. L., J. L. Madrigal, L. A. Menchén, M. A. Moro, I. Lizasoain, P. Lorenzo, and J. C. Leza. 2004. Stress increases susceptibility to oxidative/nitrosative mucosal damage in an experimental model of colitis in rats. Dig. Dis. Sci. 49: 1713-1721.
22. Fuss, I. J., M. Boirivant, B. Lacy, and W. Strober. 2002. The interrelated roles of TGF-β and IL-10 in the regulation of experimental colitis. J. Immunol. 168: 900-908.
23. Katakura, K., J. Lee, D. Rachmilewitz, G. Li, L. Eckmann, and E. Raz. 2005. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115: 695-702.
24. 2 production by stromal cells in the murine small intestine lamina propria: directing the tone of the intestinal immune response. J. Immunol. 166: 4465-4472.
25. Munn, D. H., E. Shafizadeh, J. T. Attwood, I. Bondarev, A. Pashine, and A. L. Mellor. 1999. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189: 1363-1372.
26. Sainathan, S. K., E. M. Hanna, Q. Gong, K. S. Bishnupuri, Q. Luo, M. Colonna, F. V. White, E. Croze, C. Houchen, S. Anant, and B. K. Dieckgraefe. 2008. Granulocyte macrophage colony-stimulating factor ameliorates DSS-induced experimental colitis. Inflamm. Bowel Dis. 14: 88-99.
27. Zimmerer, J. M., G. B. Lesinski, M. D. Radmacher, A. Ruppert, and W. E. Carson, III. 2007. STAT1-dependent and STAT1-independent gene expression in murine immune cells following stimulation with interferon-α. Cancer Immunol. Immunother. 56: 1845-1852.
28. van Boxel-Dezaire, A. H., and G. R. Stark. 2007. Cell type-specific signaling in response to interferon-γ. Curr. Top. Microbiol. Immunol. 316: 119-154.
29. te Velde, A. A., M. I. Verstege, and D. W. Hommes. 2006. Critical appraisal of the current practice in murine TNBS-induced colitis. Inflamm. Bowel Dis. 12: 995-999.
30. Cady, S. G., and M. Sono. 1991. 1-Methyl-DL-tryptophan, β-(3-benzofuranyl)-DL-alanine (the oxygen analog of tryptophan), and β-[3-benzo(b)thienyl]-DL-alanine (the sulfur analog of tryptophan) are competitive inhibitors for indoleamine 2,3-dioxygenase. Arch. Biochem. Biophys. 291: 326-333.
31. Hou, D. Y., A. J. Muller, M. D. Sharma, J. DuHadaway, T. Banerjee, M. Johnson, A. L. Mellor, G. C. Prendergast, and D. H. Munn. 2007. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res. 67: 792-801.
32. Stenson, W. F. 2008. Toll-like receptors and intestinal epithelial repair. Curr. Opin. Gastroenterol. 24: 103-107.
33. Cho, J. H. 2008. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8: 458-466.
34. Cario, E. 2008. Therapeutic impact of toll-like receptors on inflammatory bowel diseases: a multiple-edged sword. Inflamm. Bowel Dis. 14: 411-421.
35. Xavier, R. J., and D. K. Podolsky. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434. (Pubitemid 47123518)
36. Cario, E., G. Gerken, and D. K. Podolsky. 2007. Toll-like receptor 2 controls mucosal inflammation by regulating epithelial barrier function. Gastroenterology 132: 1359-1374. (Pubitemid 46627595)
37. Fukata, M., A. Chen, A. Klepper, S. Krishnareddy, A. S. Vamadevan, L. S. Thomas, R. Xu, H. Inoue, M. Arditi, A. J. Dannenberg, and M. T. Abreu. 2006. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 131: 862-877.
38. Obermeier, F., N. Dunger, U. G. Strauch, N. Grunwald, H. Herfarth, J. Schölmerich, and W. Falk. 2003. Contrasting activity of cytosin-guanosin dinucleotide oligonucleotides in mice with experimental colitis. Clin. Exp. Immunol. 134: 217-224.
39. Vijay-Kumar, M., H. Wu, J. Aitken, V. L. Kolachala, A. S. Neish, S. V. Sitaraman, and A. T. Gewirtz. 2007. Activation of Toll-like receptor 3 protects against DSS-induced acute colitis. Inflamm. Bowel Dis. 13: 856-864.
40. Rachmilewitz, D., K. Katakura, F. Karmeli, T. Hayashi, C. Reinus, B. Rudensky, S. Akira, K. Takeda, J. Lee, K. Takabayashi, and E. Raz. 2004. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 126: 520-528.
41. van Lierop, P. P., C. de Haar, D. J. Lindenbergh-Kortleve, Y. Simons-Oosterhuis, L. S. van Rijt, B. N. Lambrecht, J. C. Escher, J. N. Samsom, and E. E. Nieuwenhuis. 2010. T-cell regulation of neutrophil infiltrate at the early stages of a murine colitis model. Inflamm. Bowel Dis. 16: 442-451.
42. Pohlmann, A., L. C. Tilling, A. Robinson, O. Woolmer, S. McCleary, L. Kruidenier, L. C. Warnock, H. D. Lewis, A. R. Hobson, and M. F. James. 2009. Progression and variability of TNBS colitis-associated inflammation in rats assessed by contrast-enhanced and T2-weighted MRI. Inflamm. Bowel Dis. 15: 534-545.
43. Fichtner-Feigl, S., I. J. Fuss, J. C. Preiss, W. Strober, and A. Kitani. 2005. Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-κB decoy oligonucleotides. J. Clin. Invest. 115: 3057-3071.
44. Saxena, V., J. K. Ondr, A. F. Magnusen, D. H. Munn, and J. D. Katz. 2007. The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J. Immunol. 179: 5041-5053.
45. + effector T cell pool and limits intestinal inflammation in a murine model of colitis. J. Immunol. 183: 2037-2044.
46. Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107: 1643-1652.
47. Mizoguchi, E., R. J. Xavier, H. C. Reinecker, H. Uchino, A. K. Bhan, D. K. Podolsky, and A. Mizoguchi. 2003. Colonic epithelial functional phenotype varies with type and phase of experimental colitis. Gastroenterology 125: 148-161. (Pubitemid 36799116)
48. Brown, S. L., T. E. Riehl, M. R. Walker, M. J. Geske, J. M. Doherty, W. F. Stenson, and T. S. Stappenbeck. 2007. Myd88-dependent positioning of Ptgs2-expressing stromal cells maintains colonic epithelial proliferation during injury. J. Clin. Invest. 117: 258-269.
49. Taylor, M. W., and G. S. Feng. 1991. Relationship between interferon-γ, indoleamine 2,3-dioxygenase, and tryptophan catabolism. FASEB J. 5: 2516-2522.
50. Lob, S., A. Konigsrainer, R. Schafer, H. G. Rammensee, G. Opelz, and P. Terness. 2008. Levo- but not dextro-1-methyl tryptophan abrogates the IDO activity of human dendritic cells. Blood 111: 2152-2154. (Pubitemid 351451527)
51. Löb, S., A. Königsrainer, D. Zieker, B. L. Brücher, H. G. Rammensee, G. Opelz, and P. Terness. 2009. IDO1 and IDO2 are expressed in human tumors: levo- but not dextro-1-methyl tryptophan inhibits tryptophan catabolism. Cancer Immunol. Immunother. 58: 153-157.
52. Munn, D. H., and A. L. Mellor. 2004. IDO and tolerance to tumors. Trends Mol. Med. 10: 15-18.